<h4>Introduction</h4>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently recommended as one of the four pillars of treatment in heart failure (HF) with reduced ejection fraction (HFrEF). The gene discussed is SLC5A2; the disease is hydrops fetalis.